Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
暂无分享,去创建一个
[1] O. Wilhelm,et al. 128 A cellular GPI-specific phospholipase D regulates the biological function of the urokinase receptor , 1997 .
[2] H. Nielsen,et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.
[3] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[4] M. Ploug,et al. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.
[5] Michael V. Doyle,et al. Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.
[6] K. Preissner,et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.
[7] S. Rosenberg,et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.
[8] K. Danø,et al. Urokinase and urokinase receptor expression in somatic cell hybrids , 1994 .
[9] N. Brünner,et al. A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors , 1994, International journal of cancer.
[10] N. Brünner,et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.
[11] C. Cohen,et al. Screening for ovarian cancer: the role of noninvasive imaging techniques. , 1994, American journal of obstetrics and gynecology.
[12] F. Jänicke,et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.
[13] J. Soria,et al. The plasminogen‐activation system in ovarian tumors , 1993, International journal of cancer.
[14] N. Brünner,et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. , 1993, Cancer research.
[15] L. Lund,et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.
[16] I. Mizukami,et al. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. , 1992, Journal of immunology.
[17] B. Gustavsson,et al. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. , 1991, European journal of cancer.
[18] M. Ploug,et al. Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.
[19] M. Ploug,et al. Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator , 1991, Seminars in thrombosis and hemostasis.
[20] F. Blasi,et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.
[21] F. Blasi,et al. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. , 1991, The Journal of biological chemistry.
[22] R. Bast,et al. The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.
[23] A. Corti,et al. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[24] D. Belin,et al. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.
[25] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.